The Liver Meeting, American Association for Study of Liver Disease (AASLD), San Francisco
11 NOV 2018Presentations and Publications
Read about publications and presentations made by Benitec's scientific team below. For details of Benitec's announcements to NASDAQ, read details in our Investor Centre.2018
Potent and durable RNAi mediated suppression of Hepatitis B Virus infection in a mouse model by a non- viral Closed Ended Linear DNA (CELID) vector
BB-301: A Single “Silence and Replace” AAV-Based Vector for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)
The 21st Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), Chicago
18 MAY 20182017
Towards Development of a ‘Silence and Replace’ Based Approach for the Treatment of Oculopharyngeal Muscular Dystrophy
European Society of Gene & Cell Therapy (ESGCT) Congress, Berlin
18 OCT 2017
Gene therapy for oculopharyngeal muscular dystrophy
The 22nd International Annual Congress of the World Muscle Society
6 OCT 2017
Towards Development of a ‘Silence and Replace’ Based Approach for the Treatment of Oculopharyngeal Muscular Dystrophy.
Joint 10th AGCST and ASSCR Scientific Meeting, Sydney
25 MAY 2017
Significant Enhancement of Hepatitis B Virus (HBV) Suppression with Standard of Care Drugs Following Co-Administration of a DNA-Directed RNA Interference Agent in a Chimeric Mouse Model
Joint 10th AGCST and ASSCR Scientific Meeting, Sydney
24 MAY 2017
Superior suppression of Hepatitis B virus (HBV) DNA and antigen levels in a chimeric mouse model when BB-103, a DNA-Directed RNA interference (ddRNAi) agent, is coupled with standard of care drugs
EASL, The International Liver Conference 2017, Amsterdam
19 APR 2017
Combinations of a DNA-Directed RNA Interference Agent With Standard of Care Drugs Results in Superior Suppression of Hepatitis B Virus (HBV) in a Chimeric Mouse Model
EASL, The International Liver Conference 2017, Amsterdam
19 FEB 2017
PABPN1 gene therapy for oculopharyngeal muscular dystrophy
Nat. Commun. 8, 14848 doi: 10.1038/ ncomms14848 (2017)
1 JAN 20172016
BB-HB-331, a DNA-Directed RNA Interference Agent, Suppresses Hepatitis B virus (HBV) in vitro and in vivo
European Society of Gene and Cell Therapy (ESGCT) 2016 Annual Congress, Florence
18 OCT 2016